论文部分内容阅读
目的建立丙戊酸钠在癫痫患者治疗中的群体药动学模型,为临床个体化给药提供参考。方法收集我院门诊60名癫痫患者丙戊酸钠稳态血药浓度监测数据和相应的人口学数据,应用非线性混合效应模型(non linearm ixed-effectmodel,NONMEM)程序对收集的数据进行分析,建立群体药动学模型。结果建立了癫痫患者口服丙戊酸钠群体药代动力学模型:CL/F=0.959×1.04x,(x=0,1),V/F=1.35,ka=2.38 h-1,说明丙戊酸的清除率与患者性别相关,即男性患者的清除率大于女性。结论初步建立癫痫患者口服丙戊酸钠群体药动学模型,为丙戊酸钠个体化用药提供理论基础。
Objective To establish a population pharmacokinetic model of sodium valproate in the treatment of patients with epilepsy and provide a reference for clinical individualized administration. Methods The data of steady-state plasma concentration of valproate in 60 epilepsy patients from our outpatient department were collected and the corresponding demographic data were collected. The collected data were analyzed by non-linear mixed effect model (NONMEM) Establish a population pharmacokinetic model. Results The pharmacokinetic model of oral VPA in epileptic patients was established: CL / F = 0.959 × 1.04x, (x = 0,1), V / F = 1.35, ka = 2.38 h-1, Acid clearance is related to the patient’s gender, ie the clearance rate of male patients is higher than that of women. Conclusion The pharmacokinetic model of oral sodium valproate in patients with epilepsy was established initially to provide a theoretical basis for the individualized use of sodium valproate.